• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Secukinumab demonstrated high efficacy in clearing nail psoriasis: Results from posthoc analyses from the phase III programs

    Author(s)
    Reich, Kristian
    Nash, Peter
    Kirkham, Bruce
    Bao, Weibin
    Aassi, Maher
    Frueh, Jennifer A
    Gaillez, Corine
    Elewski, Boni
    Griffith University Author(s)
    Nash, Peter
    Year published
    2020
    Metadata
    Show full item record
    Abstract
    Introduction: Nail psoriasis occurs in 50%-70% of patients with psoriasis (PsO) and 60%- 80% of patients with psoriatic arthritis (PsA). Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has proven highly efficacious in the long-term treatment of the multiple manifestations of psoriatic disease, with a favorable safety profile. Here, we report the long-term results of post hoc analyses of clearing (ie achieving clear or almost clear) nail psoriasis from the secukinumab PsA FUTURE program, and from the PsO TRANSFIGURE study. Methods: These post hoc descriptive analyses focused on the year 2 NAPSI ...
    View more >
    Introduction: Nail psoriasis occurs in 50%-70% of patients with psoriasis (PsO) and 60%- 80% of patients with psoriatic arthritis (PsA). Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has proven highly efficacious in the long-term treatment of the multiple manifestations of psoriatic disease, with a favorable safety profile. Here, we report the long-term results of post hoc analyses of clearing (ie achieving clear or almost clear) nail psoriasis from the secukinumab PsA FUTURE program, and from the PsO TRANSFIGURE study. Methods: These post hoc descriptive analyses focused on the year 2 NAPSI (range: 0- 80) or mNAPSI (range: 0-130) #2 outcomes, defining clear or almost clear nails, in patients treated with 300 mg secukinumab in the TRANSFIGURE and the pooled FUTURE 2-5 studies. Analyses were performed based on observed data from all 10 fingernails. Results: In the TRANSFIGURE secukinumab 300 mg treatment group (n ¼ 66), the mean baseline NAPSI was 45.5; at year 2, 25.0% of patients had achieved a NAPSI #2. In the pooled FUTURE secukinumab 300 mg treatment group (n ¼ 220), the mean baseline mNAPSI was 20.9; at year 2, 66.7% of patients had achieved a mNAPSI #2. Conclusions: Secukinumab demonstrated a high level of efficacy in clearing nail PsO, in patients with or without concomitant PsA, even in patients with severe baseline nail involvement seen in the TRANSFIGURE study.
    View less >
    Conference Title
    Journal of the American Academy of Dermatology
    Volume
    83
    Issue
    6
    DOI
    https://doi.org/10.1016/j.jaad.2020.06.423
    Subject
    Clinical Sciences
    Science & Technology
    Life Sciences & Biomedicine
    Dermatology
    Publication URI
    http://hdl.handle.net/10072/400969
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander